The abstract is read at the publisher; the summary is JClub's.
In a French single-center cohort of hidradenitis suppurativa patients with partial biologic response, an end-of-dose effect–guided strategy was linked to IHS4 improvement, with 53.8% achieving ≥3-point response at 3–5 months.
- Why it matters: Many patients on licensed biologics for HS have only partial responses, and real-world guidance on whether to intensify dosing or add long-term antibiotics is limited.
- What they did: In a retrospective study (Jan 2022–Mar 2025), patients with insufficient response to anti-TNF-α or anti-IL-17 therapy (≥4 flares/year despite ≥3 months standard dosing) were assigned by an algorithm: end-of-dose effect (n=52) to dose intensification, otherwise (n=50) to antibiotic addition, using inverse probability weighting with doubly robust adjustment.
- The result: IHS4 fell from 7.0 (4.8) to 3.9 (4.2) at 3–5 months (P < .001), with sustained improvement at 6–12 months in 65 patients; a nominal flare-duration advantage for intensification (OR 2.56, adjusted P=.24) did not hold after multiplicity adjustment.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.